当前位置: 首页 >> 检索结果
41. Accelerometer-Measured Physical Activity After Mitral Valve Surgery: An Analysis of the UK Mini Mitral Randomized Controlled Trial.
作者: Janelle M Wagnild.;Christopher Bayliss.;Rebecca H Maier.;Emmanuel Ogundimu.;Joseph Zacharias.;Enoch F Akowuah.
来源: Circulation. 2025年152卷17期1234-1245页
Wearable accelerometer devices measure free-living physical activity and sleep without relying on self-reports. Their utility to measure and compare recovery of physical function after cardiac surgery procedures has not been previously studied in the setting of a randomized controlled trial.
42. Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial.
作者: Joseph Campain.;Catharine Griskowitz.;Chloe Newlands.;Brian L Claggett.;Ian J Kulac.;Shaina McGinnis.;Ilya Giverts.;Fabely Moreno.;Alexandra Minasian.;Cheshta Prasad.;Lillian Rupert.;Isabela Landsteiner.;Nick Iskenderian.;Caroline J Coats.;Matthew M Y Lee.;Martin S Maron.;Anjali T Owens.;Daniel L Jacoby.;Stephen B Heitner.;Stuart Kupfer.;Fady I Malik.;Amy Wohltman.;Rajeev Malhotra.;Gregory D Lewis.
来源: Circulation. 2025年152卷14期990-1002页
Post-exercise oxygen uptake recovery (VO2Rec) is slow in advanced heart failure. We sought to establish easily derived VO2Rec measures and evaluate their cardiospecificity and prognostic relevance in patients with dyspnea on exertion. We further sought to determine VO2Rec modifiability proportional to changes in cardiac function with disease-specific treatment of obstructive hypertrophic cardiomyopathy.
43. Health Status Outcomes With Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in ISCHEMIA.
作者: Chetan P Huded.;John A Spertus.;Philip G Jones.;Sean M O'Brien.;Daniel B Mark.;Sripal Bangalore.;Gregg W Stone.;David O Williams.;Harvey D White.;William E Boden.;Harmony R Reynolds.;Judith S Hochman.;David J Maron.; .
来源: Circulation. 2025年152卷12期846-858页
In ISCHEMIA (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches), an invasive strategy demonstrated better health status outcomes than a conservative strategy in patients with chronic coronary disease (CCD). Some previous studies have shown greater health status benefits with coronary artery bypass grafting (CABG) than percutaneous coronary intervention (PCI). Whether the health status benefits of invasive management in ISCHEMIA were driven primarily by participants treated with CABG is unknown.
44. Impact of Cerebral Embolic Protection on Cognitive Function After Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial.
作者: James Kennedy.;Daniel J Blackman.;Matthew Dodd.;Anna Poggesi.;Laura Read.;Zahra Jamal.;Richard Evans.;Tim Clayton.;Rajesh K Kharbanda.;David Hildick-Smith.; .
来源: Circulation. 2025年152卷18期1268-1278页
In addition to the risk of stroke, patients undergoing transcatheter aortic valve implantation (TAVI) are susceptible to a decline of neurocognitive function. This may occur because of embolization of material (eg, valve or calcium) to the brain. Cerebral embolic protection (CEP) devices are engineered to capture this debris, potentially mitigating its incidence.
45. Biomarker-Based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation: A Registry-Based, Multicenter, Randomized, Controlled Study.
作者: Jonas Oldgren.;Ziad Hijazi.;Håkan Arheden.;Anna Björkenheim.;Viveka Frykman.;Magnus Janzon.;Annica Ravn-Fischer.;Henrik Renlund.;Anders Själander.;Torbjörn Åkerfeldt.;Lars Wallentin.
来源: Circulation. 2025年152卷21期1457-1469页
The clinical use of risk scores to guide treatment decisions and improve clinical outcomes has rarely been prospectively evaluated. This study aimed to evaluate whether a biomarker-based ABC-AF risk score-guided multidimensional treatment strategy improves long-term outcomes in patients with AF.
46. Ivabradine in Patients Undergoing Noncardiac Surgery: A Randomized Controlled Trial.
作者: Wojciech Szczeklik.;Jakub Fronczek.;Zbigniew Putowski.;Anna Włudarczyk.;Jacek Górka.;Bożena Seczyńska.;Dominika Gryszówka.;Agnieszka Widawska.;Szymon Białka.;Piotr Palaczyński.;Michał Borys.;Paweł Kutnik.;Tomasz Czarnik.;Anna Szczepańska.;Marcin Możański.;Marcin Mieszkowski.;Katarzyna Kotfis.;Janusz Trzebicki.;Łukasz Sadowski.;Joanna Sołek-Pastuszka.;Paweł Grudzień.;Wojciech Mudyna.;Agnieszka Misiewska-Kaczur.;Radosław Owczuk.;Bartosz Kudliński.;Dorota Studzińska.;Jarosław Pawlik.;Adam Makowski.;Mirosław Ziętkiewicz.;Mikołaj Przydacz.;Waldemar Goździk.;Wojciech Gola.;Przemysław Jasiewicz.;Zhiguo Zhao.;Yu Shyr.;P J Devereaux.; .
来源: Circulation. 2025年152卷16期1126-1135页
Perioperative beta blockade lowers heart rate and decreases the risk of myocardial infarction but increases the risk of hypotension, death, and stroke. Ivabradine, a selective heart rate-lowering agent, may prevent prognostically important myocardial injury after noncardiac surgery (MINS) without causing hemodynamic instability.
47. Three-Year Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients With Tricuspid or Bicuspid Aortic Stenosis.
作者: Troels Højsgaard Jørgensen.;Mikko Savontaus.;Yannick Willemen.;Øyvind Bleie.;Mariann Tang.;Oskar Angerås.;Matti Niemela.;Ingibjörg J Gudmundsdóttir.;Arif Khokhar.;Ulrik Sartipy.;Hanna Dagnegård.;Mika Laine.;Andreas Rück.;Jarkko Piuhola.;Petur Petursson.;Evald H Christiansen.;Markus Malmberg.;Peter Skov Olsen.;Rune Haaverstad.;Bernard Prendergast.;Lars Sondergaard.;Hans Gustav Hørsted Thyregod.;Ole De Backer.; .
来源: Circulation. 2025年152卷19期1326-1337页
Transcatheter aortic valve replacement (TAVR) is increasingly performed in younger, low surgical risk patients. The NOTION-2 study (The Nordic Aortic Valve Intervention) reports midterm outcomes in low-risk patients age 60 to 75 years with severe tricuspid or bicuspid aortic stenosis undergoing TAVR or surgical valve replacement.
48. Diagnostic Value of Relative Flow Reserve in Patients With Prior Coronary Artery Disease: A Post Hoc Analysis of the PACIFIC-2 Trial.
作者: Roel Hoek.;Yvemarie B O Somsen.;Ruben W de Winter.;Ruurt A Jukema.;Jos W Twisk.;Pieter G Raijmakers.;Ibrahim Danad.;Juhani Knuuti.;Paul Knaapen.;Pepijn A van Diemen.;Roel S Driessen.
来源: Circ Cardiovasc Imaging. 2025年18卷10期e018574页
The relative flow reserve (RFR) derived from quantitative myocardial perfusion imaging is the ratio of absolute myocardial perfusion in a stenotic to normally perfused area and is considered the noninvasive equivalent of fractional flow reserve (FFR). In patients with prior coronary artery disease (CAD), detecting hemodynamically significant CAD using hyperemic myocardial blood flow (hMBF) is complicated by diffuse CAD and microvascular disease. In these patients, RFR may improve the diagnostic performance of myocardial perfusion imaging. Therefore, we studied the diagnostic value of RFR over hMBF in patients with prior CAD.
49. High-Dose Versus Standard-Dose Influenza Vaccine in Heart Failure: A Prespecified Analysis of the DANFLU-2 Trial.
作者: Kristoffer Grundtvig Skaarup.;Niklas Dyrby Johansen.;Daniel Modin.;Matthew M Loiacono.;Rebecca C Harris.;Marine Dufournet.;Carsten Schade Larsen.;Lykke Larsen.;Lothar Wiese.;Michael Dalager-Pedersen.;Brian L Claggett.;Katja Vu Bartholdy.;Katrine Feldballe Bernholm.;Julie Inge-Marie Helene Borchsenius.;Filip Soeskov Davidovski.;Lise Witten Davodian.;Maria Dons.;Lisa Steen Duus.;Caroline Espersen.;Frederik Holme Fussing.;Anne Marie Reimer Jensen.;Nino Emanuel Landler.;Adam Cadovius Femerling Langhoff.;Mats C H Lassen.;Anne Bjerg Nielsen.;Camilla Ikast Ottosen.;Morten Sengeløv.;Scott D Solomon.;Martin J Landray.;Gunnar H Gislason.;Lars Køber.;Pradeesh Sivapalan.;Cyril Jean-Marie Martel.;Jens Ulrik Stæhr Jensen.;Alexandre Mebazaa.;Tor Biering-Sørensen.
来源: Circ Heart Fail. 2025年18卷11期e013678页
Influenza contributes substantially to disease burden in individuals with heart failure (HF) and is an established trigger of cardiovascular and HF events. Standard-dose inactivated influenza vaccine (SD-IIV) is recommended for HF, though immune responses may be attenuated. High-dose inactivated influenza vaccine (HD-IIV) was developed to enhance immunogenicity, but its effectiveness compared with SD-IIV against hospitalization for influenza and cardiovascular disease by HF status remains uncertain.
50. Sacubitril/Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial.
作者: Torbjørn Omland.;Siri Lagethon Heck.;Espen Holte.;Albulena Mecinaj Lilleaasen.;Mari Nordbø Gynnild.;Morten Wang Fagerland.;Victoria Vinje-Jakobsen.;Anne-Katrine Lislegaard Næs.;Egil Støre Blix.;Alf Inge Larsen.;Jürgen Geisler.;Geeta Gulati.;Torgeir Wethal.
来源: Circulation. 2025年152卷16期1136-1145页
Anthracycline- and trastuzumab-associated cardiotoxicity may lead to cardiac dysfunction and dose reduction or halt of potentially life-saving adjuvant cancer therapy. Whether angiotensin receptor/neprilysin inhibitors can prevent cancer therapy-related cardiac dysfunction and injury remains to be established.
51. Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure.
作者: David D Berg.;Siddharth M Patel.;Paul M Haller.;Abby L Cange.;Michael G Palazzolo.;Andrea Bellavia.;Julia F Kuder.;Akshay S Desai.;Silvio E Inzucchi.;John J V McMurray.;Eileen O'Meara.;Subodh Verma.;Jan Bělohlávek.;Jarosław Drożdż.;Béla Merkely.;Modele O Ogunniyi.;Tomáš Drasnar.;Joseph L Izzo.;Balazs Sarman.;John E McGinty.;Krishnan Ramanathan.;Angel J Mulkay.;Andrzej Przybylski.;Christian T Ruff.;Michelle L O'Donoghue.;Sabina A Murphy.;Marc S Sabatine.;Stephen D Wiviott.; .
来源: Circulation. 2025年152卷20期1411-1422页
SGLT2 (sodium-glucose cotransporter-2) inhibitors reduce the risk of cardiovascular death or worsening heart failure (HF) in outpatients with HF. Data on initiation in patients hospitalized for HF are limited.
52. Peri-Interventional Anesthesia Strategies for Transcatheter Aortic Valve Implantation: A Multicenter, Randomized, Controlled, Noninferiority Trial.
作者: Hans-Josef Feistritzer.;Joerg Ender.;Philipp Lauten.;Tanja K Rudolph.;Volker Rudolph.;Tobias Geisler.;Steffen Massberg.;Matti Adam.;Stephan Baldus.;Samuel Sossalla.;Michael Joner.;Helge Möllmann.;Alexander Wolf.;Won-Keun Kim.;Michael A Borger.;Thilo Noack.;Harry Magunia.;Vera von Dossow.;Michael Sander.;Ursula Vigelius-Rauch.;Matthias Feuerecker.;Waseem Zakhary.;Andreas Boening.;Sabine Bleiziffer.;Sven Hohenstein.;Nadine Hoesler.;Maria Buske.;Steffen Desch.;Mohamed Abdel-Wahab.;Holger Thiele.; .
来源: Circulation. 2025年152卷22期1526-1537页
Minimalist treatment strategies for transcatheter aortic valve implantation have been widely adopted because of continued procedural evolution, but large randomized trials are lacking. The DOUBLE-CHOICE trial (Randomized Study Comparing Both Latest Generation Self-Expanding Valves and a Minimalist Approach Versus Standard of Care in Transcatheter Aortic Valve Implantation) evaluated the safety and efficacy of a minimalist approach (MA) compared with the standard of care (SoC) for transfemoral transcatheter aortic valve implantation.
53. Relationship Between Time-to-First Atrial Tachyarrhythmia Recurrence and Atrial Fibrillation Burden: Implications for Trial Design.
作者: Jason G Andrade.;Martin Aguilar.;Richard G Bennett.;Karim Benali.;Marc W Deyell.;Paul Khairy.;Laurent Macle.
来源: Circ Arrhythm Electrophysiol. 2025年18卷9期e013971页
Atrial tachyarrhythmia recurrence remains the primary end point of clinical trials evaluating therapeutic pharmacological and nonpharmacological interventions for atrial fibrillation (AF). We sought to examine the relationship between the timing of first atrial tachyarrhythmia recurrence and subsequent AF burden.
54. 2-Hydroxybenzylamine for Treatment of Atrial Fibrillation: A First-in-Human Clinical Pilot Trial.
作者: Zachary T Yoneda.;Matthew O'Neill.;Diane M Crawford.;Mingfang Ao.;Lili Sun.;Majd A El-Harasis.;Lisa Pitchford.;John A Rathmacher.;Jay Montgomery.;Sharon T Shen.;Juan Carlos Estrada.;Pablo J Saavedra.;Christopher R Ellis.;Travis Richardson.;Arvindh Kangasundram.;George H Crossley.;Wendall S Akers.;Fei Ye.;Dan M Roden.;Gregory F Michaud.;M Benjamin Shoemaker.
来源: Circ Arrhythm Electrophysiol. 2025年18卷8期e013378页
Inflammation is a common mechanism for atrial fibrillation (AF). 2-Hydroxybenzylamine (2-HOBA) is a novel therapeutic that scavenges isolevuglandins-a downstream mediator of inflammation and oxidative stress. 2-HOBA is safe and reduces AF in mice, prompting a first-in-human pilot clinical trial.
55. Impacts of Reducing Sitting Time or Increasing Sit-to-Stand Transitions on Blood Pressure and Glucose Regulation in Postmenopausal Women: Three-Arm Randomized Controlled Trial.
作者: Sheri J Hartman.;Andrea Z LaCroix.;Dorothy D Sears.;Loki Natarajan.;Rong W Zablocki.;Ruohui Chen.;Jeffrey S Patterson.;Lindsay Dillon.;James F Sallis.;Simon Schenk.;David W Dunstan.;Neville Owen.;Dori E Rosenberg.
来源: Circulation. 2025年152卷8期492-504页
Public health and clinical guidelines identify the importance of sedentary behaviors for cardiovascular diseases, particularly among postmenopausal women. The goal of this trial was to compare the behavioral and physiological impacts of 2 distinct approaches to changing sedentary behaviors.
56. Neurodevelopmental Outcomes in Early Adolescence: The Pediatric Heart Network's Single Ventricle Reconstruction Trial.
作者: Thomas A Miller.;Binu Sharma.;Russell Gongwer.;Felicia L Trachtenberg.;Jane W Newburger.;Caren S Goldberg.;Kathryn E Gustafson.;J William Gaynor.;Jodie K Votava-Smith.;Linda M Lambert.;Renee Sananes.;Mary C Kral.;Rocky Tsang.;Kimberley P Heinrich.;James Cnota.;Amee Shah.;Dawn Ilardi.; .
来源: Circulation. 2025年152卷17期1246-1261页
Neurodevelopmental and functional impairments are among the most consequential morbidities for survivors of hypoplastic left heart syndrome after staged single ventricle surgical palliation. The SVRIII trial (Long-Term Outcomes of Children With Hypoplastic Left Heart Syndrome and the Impact of Norwood Shunt Type) enrolled adolescents, who were randomized to different surgical shunt types at the time of Norwood procedure as neonates, for multifaceted in-person evaluation. This study reports their neurodevelopmental outcomes.
57. Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early After Surgical Bioprosthetic Valve Replacement: A Randomized Clinical Trial.
作者: Chisato Izumi.;Masashi Amano.;Yusuke Yoshikawa.;Satsuki Fukushima.;Hitoshi Yaku.;Kiyoyuki Eishi.;Taichi Sakaguchi.;Nobuhisa Ohno.;Arudo Hiraoka.;Kenji Okada.;Yoshikatsu Saiki.;Takashi Miura.;Tatsuhiko Komiya.;Manabu Minami.;Haruko Yamamoto.;Katsuhiro Omae.; .
来源: Circ Cardiovasc Interv. 2025年18卷7期e015108页
Anticoagulant therapy with vitamin K antagonists is recommended in the current guidelines for 3 to 6 months following bioprosthetic valve replacement. However, in the era of direct oral anticoagulants, there is a paucity of evidence regarding the efficacy and safety of direct oral anticoagulants in this patient group.
58. Guideline-Directed Medical Therapy Use in the STRONG-HF Trial.
作者: Xiang Zhang.;Beth Davison.;Marianna Adamo.;Mattia Arrigo.;Jan Biegus.;Ovidiu Chioncel.;Alain Cohen Solal.;Gad Cotter.;Christopher Edwards.;Antoine Kimmoun.;Carolyn S P Lam.;Alexandre Mebazaa.;Marco Metra.;Maria Novosadova.;Peter S Pang.;Karen Sliwa.;Koji Takagi.;Adriaan A Voors.;Justin A Ezekowitz.
来源: Circ Heart Fail. 2025年18卷9期e012716页
Assessment of medication changes in heart failure trials and registries is complex and may not capture the entirety of care. A comprehensive and standardized method is needed. We used different methods to assess the use of guideline-directed medical therapies (GDMT) and verified the association between GDMT intensity score with the STRONG-HF trial (Safety, Tolerability and Efficacy of Rapid Optimization, Helped by NT-proBNP Testing of Heart Failure Therapies) clinical outcomes.
59. Hypokalemia During Decongestion With Loop Diuretics and Hydrochlorothiazide, a Post Hoc Analysis of the CLOROTIC Trial.
作者: Alicia Conde-Martel.;Marta Hernández-Meneses.;José Luís Morales-Rull.;Jesús Casado.;Margarita Carrera-Izquierdo.;Marta León.;Marta Sánchez-Marteles.;Melitón Francisco Dávila-Ramos.;Carolina Hernández-Carballo.;Pau Llácer.;Mari Carmen Moreno-García.;Prado Salamanca-Bautista.;Francesc Formiga.;Luís Manzano.;Joan Carles Trullàs.
来源: Circ Heart Fail. 2025年18卷9期e012914页
In patients with acute heart failure, the addition of hydrochlorothiazide (HCTZ) to furosemide increased the diuretic response in the CLOROTIC trial (Combining Loop with Thiazide Diuretics for Decompensated Heart Failure). The aim of this subanalysis was to evaluate the incidence and risk factors for hypokalemia, and its impact on mortality and readmissions.
60. Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial.
作者: Samer Al Said.;Siddharth M Patel.;Robert P Giugliano.;David A Morrow.;Erica L Goodrich.;Sabina A Murphy.;Bruce Hug.;Sanobar Parkar.;Shih-Ann Chen.;Shaun G Goodman.;Boyoung Joung.;Robert G Kiss.;Wojciech Wojakowski.;Jeffrey I Weitz.;Dan Bloomfield.;Marc S Sabatine.;Christian T Ruff.
来源: Circulation. 2025年152卷5期290-296页
Combining antiplatelet therapy (APT) with conventional anticoagulants increases the risk of bleeding. In the AZALEA-TIMI 71 trial (Safety and Tolerability of Abelacimab [MAA868] vs Rivaroxaban in Patients With Atrial Fibrillation), the novel factor XI inhibitor abelacimab significantly reduced the risk of bleeding compared with rivaroxaban in patients with atrial fibrillation. Whether the safety of combination antithrombotic therapy differs in the context of factor XI inhibition has not been well characterized.
|